Drugs in other drugs: a new look at drugs as fragments

Drug Discovery Today

Volumn 12, Issue 1-2, 2007, Pages 71-79

  Siegel, Miles G ^a   Vieth, Michal ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; AMPICILLIN; ARBUTAMINE; BENZOIC ACID; CARBIDOPA; CEFETAMET; CEFTIZOXIME; CYCLIZINE; DEXFENFLURAMINE; DOPAMINE; ETILEFRINE; HYDROQUINONE; HYDROXYAMPHETAMINE; ISOETARINE; LEVORPHANOL; LORMETAZEPAM; MEDAZEPAM; METHAMPHETAMINE; METHYLDOPA; OXYBATE SODIUM; PHENTERMINE; PREDNISOLONE; SALICYLAMIDE; SAQUINAVIR; SULBACTAM; SULFANILAMIDE; SULTAMICILLIN; UNINDEXED DRUG; XYLOSE;

ANALYSIS; DRUG MARKETING; DRUG STRUCTURE; REVIEW;

DRUG DESIGN; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845736461     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.11.011     Document Type: Review

References (26)

1. Lipinski C., and Hopkins A. Navigating chemical space for biology and medicine. Nature 432 (2004) 855-861
2. Leeson P.D., and Davis A.M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 47 (2004) 6338-6348
3. Vieth M., et al. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47 (2004) 224-232
4. Wenlock M.C., et al. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46 (2003) 1250-1256
5. Vieth M., and Sutherland J.J. Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49 (2006) 3451-3453
6. Proudfoot J.R. The evolution of synthetic oral drug properties. Bioorg. Med. Chem. Lett. 15 (2005) 1087-1090
7. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
8. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
9. Oprea T.I. Current trends in lead discovery: Are we looking for the appropriate properties. J. Comp-Aided Mol. Des. 16 (2002) 325-334
10. Muegge I. Selection criteria for drug-like compounds. Med. Res. Rev. 23 (2003) 302-321
11. Blake J.F. Examination of the computed molecular properties of compounds selected for clinical development. Biotechniques 34 (2003) S16-S20
12. Lajiness M., et al. Molecular properties that influence oral drug-like behavior. Curr. Opin. Drug Discov. Devel. 7 (2004) 400-407
13. Hann M.M., et al. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41 (2001) 856-864
14. Hann M.M., and Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8 (2004) 255-263
15. Erlanson D.A., et al. Fragment-based drug discovery. J. Med. Chem. 47 (2004) 3463-3482
16. Zartler E.R., and Shapiro M.J. Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 9 (2005) 366-370
17. Rees D.C., et al. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3 (2004) 660-672
18. Lewell X.Q., et al. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 38 (1998) 511-522
19. Vieth M., and Siegel M. Structural fragments in marketed oral drugs. In: Erlanson J. (Ed). Fragment based drug discovery (2006), Wiley-VCH 123-135
20. MICROMEDEX, T. (2003) MICROMEDEX(R) healthcare series (http://www.micromedex.com)
21. Daylight chemical information systems, I. (2002) CLOGP (http://www.daylight.com)
22. Paolini G.V., et al. Global mapping of pharmacological space. Nat. Biotechnol. 24 (2006) 805-815
23. Wermuth C.G. The "SOSA" approach - an alternative to high throughput screening. Med. Chem. Res. 10 (2001) 431-439
24. Wermuth C.G. Selective optimization of side activities: another way or drug discovery. J. Med. Chem. 47 (2004) 1303-1314
25. Caron P.R., et al. Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5 (2001) 464-470
26. Raju T.N. The Nobel chronicles. Lancet 355 (2000) 1022